| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 426 / 428 | 0th | Q4 |
Compare journals
Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Revisiones en Cancer
Revisiones en Cancer is Scopus-indexed (Q4, CiteScore 0). Published by ARAN Ediciones S.L.
Checked against the index lists dated .
ISSN 0213-8573Verify ISSN ↗
Publisher: ARAN Ediciones S.L
Cost to publish: No APC data — check the publisher
Not listed in: Web of Science, DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Quick answers
Is Revisiones en Cancer indexed in Scopus?
Yes — actively indexed in Scopus, coverage 2021–present (also 1992–2019), best quartile Q4, CiteScore 0.
What quartile is Revisiones en Cancer in Scopus?
Revisiones en Cancer is Q4 in Oncology (rank 426 of 428), by CiteScore 2025.
What is the impact factor of Revisiones en Cancer?
Revisiones en Cancer is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 0, quartile Q4, 0th percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.102, quartile Q4, with an H-index of 2.
Who publishes Revisiones en Cancer and what is its ISSN?
Revisiones en Cancer is published by ARAN Ediciones S.L. Its ISSN is 0213-8573.
Is Revisiones en Cancer in Web of Science?
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
Is Revisiones en Cancer open access?
No — it is not registered as an open-access journal in DOAJ or Scopus.
How well cited is Revisiones en Cancer? — open metrics via OpenAlex
Revisiones en Cancer has an h-index of 4 and a 2-year mean of 0.06 citations per paper (OpenAlex). Its Scopus CiteScore is 0, quartile Q4. On 2-year citations it ranks #397 of 424 Scopus journals in Oncology.
Revisiones en Cancer published 18 papers in 2025; its busiest recent year was 2024 with 44. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
Are there integrity warnings for Revisiones en Cancer? — indicators, not proof of misconduct
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
- Scopus statusActive
- Retracted papers None recorded
- Problematic Paper Screener flags None flagged
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Official sources & links
Community experience: reader comments on this journal
Related journals
8 journalsIndex data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.